期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 59, 期 3, 页码 1505-1509出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.03894-14
关键词
-
资金
- University of Pittsburgh Medical Center
- National Center for Advanced Translational Sciences of the National Institutes of Health (NIH) [KL2 RR024154]
Treatment failures of a carbapenem-colistin regimen among patients with bacteremia due to sequence type 258 (ST258), KPC-2-producing Klebsiella pneumoniae were significantly more likely if both agents were inactive in vitro, as defined by a colistin MIC of >2 mu g/ml and the presence of either a major ompK36 porin mutation (guanine and alanine insertions at amino acids 134 and 135 [ins aa 134-135 GD], IS5 promoter insertion [P = 0.007]) or a doripenem MIC of >8 mu g/ml (P = 0.01). Major ompK36 mutations among KPC-K. pneumoniae strains are important determinants of carbapenem-colistin responses in vitro and in vivo.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据